Used as an intermediate in the synthesis of certain pharmaceutical compounds, particularly in the development of carbonic anhydrase inhibitors. These inhibitors are relevant in treating conditions such as glaucoma, epilepsy, and edema. The sulfonamide group contributes to high affinity for carbonic anhydrase enzymes, while the cyclopropyl moiety enhances metabolic stability and influences pharmacokinetic properties. It is primarily employed in research settings for designing new bioactive molecules rather than as a standalone therapeutic agent.